Adams Kendra 4
4 · C4 Therapeutics, Inc. · Filed Mar 8, 2024
Insider Transaction Report
Form 4
Adams Kendra
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-03-07−45,000→ 0 totalExercise: $22.71Exp: 2032-02-13→ Common Stock (45,000 underlying) - Award
Stock Option (Right to Buy)
2024-03-07+45,000→ 45,000 totalExercise: $19.00Exp: 2032-02-13→ Common Stock (45,000 underlying)
Footnotes (2)
- [F1]On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 14, 2022, subject to the Reporting Person's continued service on each vesting date.